Carlos L. Arteaga, M.D., a devoted cancer researcher and clinician, was named Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in September 2017. He also serves as Associate Dean of Oncology Programs. Dr. Arteaga is internationally recognized for his work in laboratory-based translational research and advancing the care of breast cancer patients. The majority of Dr. Arteaga’s career has been as a physician-scientist in Medical Oncology at the Vanderbilt-Ingram Cancer Center of Vanderbilt University, where he served as Associate Director for Translational/Clinical Research and Director of the Center for Cancer Targeted Therapies. At Vanderbilt, he also led a successful translational research program that includes a National Cancer Institute/National Institutes of Health SPORE award in breast cancer. He is a member of the American Society for Clinical Investigation and the Association of American Physicians. He has earned numerous accolades from the American Cancer Society, the American Association for Cancer Research (AACR), Susan G. Komen for the Cure Foundation, and the American Society of Clinical Oncology. A former President of the AACR, he serves on the boards of advisors of several cancer centers and breast cancer programs. Dr. Arteaga earned his medical degree from Facultad de Ciencias Médicas at the Universidad de Guayaquil in Ecuador. He trained in Internal Medicine at Emory University and in Medical Oncology at the University of Texas Health Science Center at San Antonio.
- Medical School
- Universidad de Guayaquil, Ecuador (1980)
- Emory University School of Medicine (1984), Internal Medicine
- University of Texas Health Science Center, San Antonio (1988), Hematology Oncology
- Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy.
- Stricker T, Arteaga CL Cancer Discov 2015 Nov 5 11 1124-6
- NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
- Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM J Natl Compr Canc Netw 2015 Nov 13 11 1337-46
- In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
- Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K Nat. Genet. 2015 Oct 47 10 1212-9
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
- Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD J. Clin. Oncol. 2015 Aug 33 24 2623-31
- P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
- Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW Oncogene 2015 Jul 34 30 3968-76
- Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
- Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL Mol. Cell Proteomics 2015 Jul 14 7 1959-76
- Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.
- Abramson RG, McGhee CR, Lakomkin N, Arteaga CL Acad Radiol 2015 Jun 22 6 779-86
- Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.
- Ju JH, Oh S, Lee KM, Yang W, Nam KS, Moon HG, Noh DY, Kim CG, Park G, Park JB, Lee T, Arteaga CL, Shin I Cell Death Differ. 2015 Apr 22 4 665-76
- Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts.
- Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC J Biomed Opt 2015 Feb 20 2 26004
- Utility of [18?F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.
- Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE Mol Imaging Biol 2015 Feb 17 1 119-28